Portage Biotech to Present at Oppenheimer’s 33rd Annual Healthcare Conference

Rhea-AI Summary

Portage Biotech Inc. (NASDAQ: PRTG) announced its participation in Oppenheimer's 33rd Annual Healthcare Conference from March 13-15, 2023. The management team is scheduled to present on March 14, 2023, from 2:00-2:30 PM ET. Interested investors can watch the presentation via a live webcast at this link. Additionally, one-on-one investor meetings will be held during the event. A replay of the presentation will be available on the company's Investor Relations website following the event.

Portage specializes in innovative immuno-oncology therapies, focusing on small molecule engagers and adenosine antagonists.

WESTPORT, Conn., March 07, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that the Company’s management team will be presenting virtually at Oppenheimer’s 33^rd Annual Healthcare Conference on March 13-15, 2023. Presentation details are below:

Oppenheimer 33^rd Annual Healthcare Conference

Date / Time:	Tuesday, March 14, 2023 at 2:00 – 2:30pm ET
Webcast:	https://wsw.com/webcast/oppenheimer27/prtg/2813041

The Portage management team will participate in one-on-one investor meetings during the event. Investors interested in meeting with Portage at the conferences should contact their Oppenheimer representative.

A replay of the presentation will also be available at the Investor Relations section of the company's website at https://ir.portagebiotech.com/news-and-events/events.

About Portage Biotech Inc.
Portage is a clinical-stage immuno-oncology company advancing multi-targeted therapies to extend survival and significantly improve the lives of patients with cancer. Lead programs in the Portage portfolio include first-in-class invariant natural killer T cell (iNKT) small molecule engagers and best-in-class adenosine antagonists. These programs are being advanced using innovative trial designs and translational data to identify the patient populations most likely to benefit from treatment. The Company’s unique business model leverages a strong network of academic experts and large pharma partners to rapidly and efficiently advance multiple products. For more information, please visit www.portagebiotech.com, follow us on Twitter at @PortageBiotech or find us on LinkedIn at Portage Biotech Inc.

FOR MORE INFORMATION, PLEASE CONTACT:

Investor Relations
Chuck Padala
chuck@lifesciadvisors.com

Media Relations
Gwendolyn Schanker
gschanker@lifescicomms.com

FAQ

When is Portage Biotech's presentation at the Oppenheimer Healthcare Conference?

Portage Biotech will present on March 14, 2023, from 2:00-2:30 PM ET.

How can I watch Portage Biotech's presentation?

You can watch the presentation live via webcast at https://wsw.com/webcast/oppenheimer27/prtg/2813041.

Is there a replay available for Portage Biotech's presentation?

Yes, a replay will be available on the Investor Relations section of Portage Biotech's website after the event.

What type of therapies does Portage Biotech focus on?

Portage Biotech focuses on novel multi-targeted immuno-oncology therapies, including small molecule engagers and adenosine antagonists.

Who can investors contact for meetings during the Oppenheimer Conference?

Investors interested in one-on-one meetings should contact their Oppenheimer representative.